Description

Aminazin (Chlorpromazine) Ampoules 2.5% 2 ml. №10

Ingredients

Active ingredient: Chlorpromazine 2.5%
Other ingredients: Sodium chloride, water for injection.

Dosage

Dosage: The usual adult dose is 25-50 mg every 6-8 hours, not to exceed 400 mg per day. Dosage may vary based on the condition being treated. Consult a healthcare professional for personalized recommendations.

Indications

Indications: Aminazin ampoules are indicated for the management of various psychiatric conditions such as schizophrenia, bipolar disorder, and severe behavioral problems.

Contraindications

Contraindications: Do not use Aminazin if you have a history of hypersensitivity to chlorpromazine or other phenothiazines. It is contraindicated in patients with CNS depression, comatose states, or severe hypotension.

Directions

Directions: A healthcare professional should administer Aminazin via intramuscular or intravenous injection. Follow the recommended dosage and administration guidelines strictly.

Scientific Evidence

Chlorpromazine, the active ingredient in Aminazin, exerts its antipsychotic effects by antagonizing dopamine receptors in the brain. Studies have shown its efficacy in managing acute psychotic episodes and reducing agitation in patients with schizophrenia. Research also suggests that chlorpromazine may have antiemetic properties, making it useful in managing nausea and vomiting.

Additional Information

Aminazin should be used with caution in elderly patients due to an increased risk of hypotension and sedation. It may also cause side effects such as drowsiness, dry mouth, and blurred vision. Monitoring for adverse reactions is essential during treatment with Aminazin.

Pharmacological Effects: Chlorpromazine acts by blocking dopamine receptors in the brain, leading to a reduction in psychotic symptoms. It also exhibits antiemetic properties, making it effective in managing nausea and vomiting.

Clinical Trials: Clinical trials have demonstrated the efficacy of chlorpromazine in treating schizophrenia and other psychiatric disorders. A study published in the Journal of Clinical Psychopharmacology showed that chlorpromazine was effective in reducing positive symptoms of schizophrenia compared to a placebo.